NCT05638698View on ClinicalTrials.gov

Tg01 Vaccine / Qs-21 Stimulon™ With Or Without Balstilimab As Maintenance Therapy Following Adjuvant Chemotherapy In Patients With Resected Pancreatic Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

December 15, 2022

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2025

Conditions
Pancreas Cancer
Interventions
BIOLOGICAL

TG01 Vaccine

used to assess molecular disease control rate when combined with other interventional methods.

DRUG

QS-21

used to assess molecular disease control rate when combined with other interventional methods.

DRUG

Balstilimab

used to assess molecular disease control rate when combined with other interventional methods.

Trial Locations (5)

64064

University of Kansas Cancer Center - Lee's Summit, Lee's Summit

64154

University of Kansas Cancer Center - North, Kansas City

66205

University of Kansas Cancer Center - Westwood, Westwood

66208

University of Kansas Cancer Center - Clinical Research Center, Fairway

66210

University of Kansas Cancer Center - Overland Park, Overland Park

All Listed Sponsors
collaborator

Targovax ASA

INDUSTRY

lead

University of Kansas Medical Center

OTHER